Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, ...

Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts.

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Thank you for joining us for Eli Lilly & Company's Q1 2025 earnings call ... Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than ...

UBS has adjusted its outlook on Eli Lilly and Company (NYSE: LLY), reducing its stock price target to $1,050 while maintaining a Buy rating. This move ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.